Princeton University will not begin to offer Novartis' meningitis B vaccine to Bexsero to students until next week, but health officials are already considering expanding the campaign to another university. An outbreak at the University of California, Santa Barbara, is the cause of the latest concerns.
Novartis has been wanting to get its meningitis vaccine Bexsero into the U.S. market. Thanks to an outbreak at Princeton University, that's going to happen sooner than the Swiss drugmaker thought. Ahead of FDA approval, in fact.
As a meningitis outbreak has slowly spread across Princeton University over the past 8 months, the case for vaccinating students has grown stronger. The only hitch is that the vaccine, Novartis' Bexsero, has yet to win approval in the U.S. Now, though, health authorities are willing to work around this obstacle.
Novartis' Bexsero may be the only vaccine approved for life-threatening meningitis B, but that wasn't enough to convince the U.K.'s Joint Committee on Vaccination and Immunisation to add it to Britain's routine vaccination schedule.
Bringing a new vaccine to market in Europe is tough. After winning approval at the European level, manufacturers must show the value of the product to national decision makers. Novartis is in the middle of this process with its meningitis B vaccine, and still has a long way to go.
Pfizer catapulted itself into the vaccine big leagues in 2009 by merging with Wyeth, and continued demand for Prevnar 13 has seen it consolidate its position. Analysts predict its sales could dwarf other vaccines--hitting $6.7 billion in 2018--but recent quarters suggest it will be a bumpy ride.
Novartis nabbed EU approval of Bexsero, a meningitis B vaccine the company has been banking on to bolster its lagging vaccine unit.
Novartis has won European approval of Bexsero, its new meningitis B vaccine, which is central to the Big Pharma's drive to grow its big vaccine unit.
Novartis, still riding high on a European Medicine Agency committee backing of its meningitis vaccine Bexsero, confirmed more upbeat results from a study showing the shot offered broad protection to infants.
Novartis ($NVS) hit a key turning point with its vaccines division when a European Union committee backed the company's Bexsero meningitis shot.